Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims largely align with the FDA-approved Lipitor label for drug interactions, myopathy risk with interacting agents, and dosing considerations in the context of specific co-medications. It correctly identifies strong CYP3A4 inhibitors, cyclosporine interactions, and monitoring concepts. It includes some statements not supported by the label (e.g., universal gemfibrozil avoidance, universal 20 mg cap across all interactions) and omits some label details (e.g., explicit contraindication language for active liver disease). Overall, performance is generally accurate with a few unsupported or overly generalized claims.
Category Scores
Accurate Statements
Lipitor interacts with many medications via CYP3A4, which metabolizes it.
supported
This can raise atorvastatin levels, increasing muscle damage (myopathy or rhabdomyolysis) risk.
supported
Gemfibrozil (Lopid) and fenofibrate raise myopathy risk when used with Lipitor.
supported
Clarithromycin inhibits CYP3A4.
supported
Erythromycin inhibits CYP3A4.
supported
Itraconazole inhibits CYP3A4.
supported
Inhibiting CYP3A4 boosts atorvastatin exposure.
supported
Ritonavir increases atorvastatin levels significantly.
supported
Lopinavir/ritonavir increases atorvastatin levels significantly.
supported
Saquinavir increases atorvastatin levels significantly.
supported
Amiodarone elevates myopathy risk when coadministered with Lipitor.
supported
Dronedarone elevates myopathy risk when coadministered with Lipitor.
supported
Cap Lipitor at 20 mg daily when combined with these drugs.
partial
Cyclosporine increases atorvastatin levels 8-fold.
supported
Limit atorvastatin to 10 mg daily when coadministered with cyclosporine.
supported
These interactions amplify statin toxicity, with symptoms like unexplained muscle pain or weakness.
supported
Grapefruit juice inhibits CYP3A4.
supported
Grapefruit juice raises atorvastatin blood levels.
supported
Avoid large amounts (over 1 quart daily).
supported
Providers often lower Lipitor dose.
supported
Providers switch statins (e.g., to pravastatin, less affected by CYP3A4).
supported
Providers monitor CK levels and symptoms.
supported
Always check with a pharmacist or use tools like drug interaction checkers before starting new meds.
supported
Risk increases with high Lipitor doses (40-80 mg).
supported
Risk increases in elderly patients.
supported
Risk increases with kidney or liver issues.
supported
Risk increases with multiple interacting drugs.
supported
Unsupported Statements
Avoid gemfibrozil with Lipitor.
Label does not explicitly state to avoid gemfibrozil; it notes risk with fibric acid derivatives and cautions with monitoring.
Ketoconazole inhibits CYP3A4.
Label lists itraconazole as an example; ketoconazole is not explicitly cited in the provided sections.
Posaconazole inhibits CYP3A4.
Posaconazole is not cited in the provided interaction sections.
Fosamprenavir increases atorvastatin levels significantly.
Not specified in the label's interaction sections provided.
Nelfinavir increases atorvastatin levels significantly.
Not specified in the label's interaction sections provided.
Tipranavir/ritonavir increases atorvastatin levels significantly.
Not specified in the label's interaction sections provided.
Diltiazem requires capping Lipitor at 40 mg.
No label-supported cap of 40 mg with diltiazem in the provided sections.
St. John's wort speeds up metabolism, potentially reducing Lipitor effectiveness.
Not explicitly listed in the provided label sections.
Asian patients may need lower doses due to genetic factors affecting metabolism.
No ethnicity-based dosing guidance is provided in the supplied label sections.
Contradictions
Important Omissions
Explicit contraindication language for active liver disease is present in the label but not addressed by the claims (i.e., contraindication language is not stated in the AI-generated claims).
Importance:
High
No explicit boxed-warning language is identified in the claims evaluation, though the label discusses rhabdomyolysis risk with certain interactions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most high-risk interactions (e.g., with strong CYP3A4 inhibitors, cyclosporine, and certain HIV protease inhibitors) are correctly identified; a few overstated or unsupported statements exist, but the overall risk framing aligns with label warnings about myopathy/rhabdomyolysis with interacting drugs.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some statements are not universally supported by the label (e.g., universal gemfibrozil avoidance, universal 20 mg cap). Include conditional language reflecting the label (e.g., dose adjustments or cautions by drug pair) and ensure explicit contraindication language (active liver disease) is covered.
Suggested Improvement
Remove or qualify statements that are not explicitly supported by the label; add complete references to dosing recommendations per 2.6 and 7.1/7.3; ensure all assertions about specific agents (ketoconazole, posaconazole, etc.) are limited to those explicitly listed in the label; address the label's explicit contraindications (active liver disease) within the claims evaluation.